MCID: VGN017
MIFTS: 45

Vaginal Cancer malady

Categories: Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Vaginal Cancer

About this section
Sources:
11Disease Ontology, 13DISEASES, 27GTR, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 38MedlinePlus, 39MeSH, 45NCIt, 48NIH Rare Diseases, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Vaginal Cancer:

Name: Vaginal Cancer 11 48 38 13
Vaginal Carcinoma 54 27
Vaginal Neoplasms 39 68
Vaginal Malignant Epithelial Tumor 54
Malignant Neoplasm of Vagina 11
Malignant Vaginal Neoplasm 68
Malignant Tumor of Vagina 11
 
Malignant Vaginal Tumor 11
Neoplasm of Vagina 11
Vaginal Neoplasia 68
Vagina Carcinoma 68
Vagina Neoplasm 11
Vaginal Tumor 11

Classifications:



External Ids:

Disease Ontology11 DOID:119
ICD1030 C52
ICD9CM32 184.0
MeSH39 D014625
NCIt45 C3437, C7410
Orphanet54 ORPHA180247
UMLS via Orphanet69 C0262659
ICD10 via Orphanet31 C52

Summaries for Vaginal Cancer

About this section
MedlinePlus:38 Vaginal cancer is a rare type of cancer. it is more common in women 60 and older. you are also more likely to get it if you have had a human papillomavirus (hpv) infection or if your mother took diethylstilbestrol (des) when she was pregnant. doctors prescribed des in the 1950's to prevent miscarriages. you are also at higher risk if you have had abnormal cells in the vagina, cervix, or uterus. it often doesn't have early symptoms. however, see your doctor if you notice bleeding that is not your period a vaginal lump pelvic pain a pap test can find abnormal cells that may be cancer. vaginal cancer can often be cured in its early stages. treatment might include surgery, radiation therapy, and chemotherapy. nih: national cancer institute

MalaCards based summary: Vaginal Cancer, also known as vaginal carcinoma, is related to vaginal disease and vaginitis, and has symptoms including pelvic pain and pruritus of vagina. An important gene associated with Vaginal Cancer is HLA-G (Major Histocompatibility Complex, Class I, G). Affiliated tissues include the vagina, testes and cervix, and related mouse phenotypes are Decreased viability and Increased Nanog expression.

Disease Ontology:11 A female reproductive system cancer that is located in the vagina.

Wikipedia:71 Vaginal cancer is any type of cancer that forms in the tissues of the vagina. Primary vaginal cancer is... more...

Related Diseases for Vaginal Cancer

About this section

Graphical network of diseases related to Vaginal Cancer:



Diseases related to vaginal cancer

Symptoms & Phenotypes for Vaginal Cancer

About this section

UMLS symptoms related to Vaginal Cancer:


pelvic pain, pruritus of vagina

GenomeRNAi Phenotypes related to Vaginal Cancer according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00381-A-110.5MAPK8IP1, MYLK2
2GR00371-A-310.3EIF4A3, MAPK8IP1
3GR00366-A-359.5EIF4A3, SLC10A2

Drugs & Therapeutics for Vaginal Cancer

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Gardasil16 44 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
FDA Label: Gardasil
Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:16 GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets: -
Mechanism of Action:16 
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Vaginal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 301)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Nandrolone decanoateapproved, illicitPhase 431360-70-39677
Synonyms:
19-nortestosterone decanoate
Deca-durabolin
 
Nandrolone 17β-decanoate
Norandrostenolone decanoate
Nortestosterone decanoate
2
Nandroloneapproved, illicitPhase 431434-22-09904, 229455
Synonyms:
(17-beta)-17-Hydroxyestr-4-en-3-one
(17beta)-17-hydroxyestr-4-en-3-one
(8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
17-Hydroxy-Estr-4-Ene-3-One
17-beta-Hydroestr-4-en-3-one
17beta-Hydroxy-19-nor-4-androsten-3-one
17beta-Hydroxy-19-norandrost-4-en-3-one
17beta-Hydroxy-4-estren-3-one
17beta-hydroxyestr-4-en-3-one
19-Norandrostenolone
19-Nortestosterone
19NTPP
4-Estren-17beta-ol-3-one
434-22-0
46476_FLUKA
46476_RIEDEL
74640_ALDRICH
74640_FLUKA
AC-15207
AC1L1U32
C07254
C18H26O2
CHEBI:7466
CHEMBL757
CID9904
CPD000058610
D08250
Deca-Durabolin
Durabolin
EINECS 207-101-0
Estr-4-en-3-one, 17-hydroxy-, (17-beta)- (9CI)
Estr-4-en-3-one, 17-hydroxy-, (17beta)- (9CI)
Estr-4-en-3-one, 17beta-hydroxy- (8CI)
Estrenolone
HMS2051I04
HSDB 3368
LMST02010044
LS-64851
LT03330030
MLS002222325
 
Menidrabol
MolPort-003-849-312
N7252_SIGMA
NCGC00159416-02
NPP
NSC 3351
NTPP
Nadrolone
Nadrolone phenylpropionate
Nandrolin
Nandrolon
Nandrolon phenylpropionate
Nandrolona
Nandrolona [INN-Spanish]
Nandrolone (INN)
Nandrolone Base
Nandrolone Decanoate
Nandrolone Decanoic acid
Nandrolone Phenpropionate
Nandrolone phenpropionate
Nandrolone phenylpionate
Nandrolone phenylpropionate
Nandrolonum
Nandrolonum [INN-Latin]
Norandrolone phenyl propionate
Norandrostenolon
Norandrostenolone
Norandrostenolone phenylpropionate
Nortestonate
Nortestosterone
Nortestosterone phenylpropionate
Nortestosteronum
Oestrenolon
SAM001246751
SMR000058610
Testosterone phenylpropionate
U 2410
UNII-6PG9VR430D
ZINC03814379
decadura
decadura (TN)
nandrolone
3
GoserelinapprovedPhase 4, Phase 322965807-02-547725, 5311128
Synonyms:
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
AC1NSK1T
CID5311128
Goserelin
Goserelin acetate
 
HMS2089D16
HS-2015
ICI-118630
MolPort-006-823-831
ZD-9393
Zoladex
goserelin
4DienogestapprovedPhase 44065928-58-7
5
Estradiolapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3128350-28-25757, 53477783
Synonyms:
(+)-3,17b-Estradiol
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17beta)-Estra-1,3,5(10)-triene-3,17-diol
.alpha.-Estradiol
.alpha.-Oestradiol
.beta.-Estradiol
.beta.-Oestradiol
1,3,5[10]-Estratriene-3,17beta-diol 3-sulfate
1,3,5[10]-Estratriene-3,17beta-diol 3-sulphate
13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol
17 beta-Estradiol
17-.BETA.-Estradiol
17-E
17-beta
17-beta-OH-estradiol
17-beta-estradiol
17.beta.-Estradiol
17.beta.-Oestradiol
17E
17b-Estradiol
17b-Oestradiol
17beta Oestradiol
17beta oestradiol
17beta-Estra-1,3,5(10)-triene-3,17-diol
17beta-Estradiol
17beta-Oestradiol
1jgl
1qkt
1qku
2d06
3,17-Epidihydroxyestratriene
3,17-beta-Estradiol
3,17-beta-Oestradiol
3,17.beta.-Estradiol
3,17b-Dihydroxyestra-1,3,5(10)-triene
3,17b-Estradiol
3,17beta-Estradiol
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulfate
3,17beta-dihydroxy-1,3,5[10]-estratriene 3-sulphate
50-28-2
73459-61-7
873662-39-6
AC-10460
AC1L1L2K
Aerodiol
Agofollin
Alora
Altrad
Amnestrogen
Aquadiol
B-Estradiol
BEDOs
BIDD:ER0125
BIDD:PXR0065
BPBio1_000532
BSPBio_000482
BSPBio_001065
Bardiol
Benzhormovarine
Beta-estradiol
Bio-0812
Bio-E-Gel
Bio1_000403
Bio1_000892
Bio1_001381
Bio2_000363
Bio2_000843
C00951
C18H24O2
CCRIS 280
CHEBI:16469
CHEMBL135
CID5757
CMC_11154
CPD-352
CPD000059126
Climaderm
Climara
Climara (TN)
Climara Forte
Compudose
Compudose 200
Compudose 365
Corpagen
D-3,17beta-Estradiol
D-Estradiol
D-Oestradiol
D00105
DB00783
Dermestril
Destradiol
Dihydro-Theelin
Dihydrofollicular hormone
Dihydrofolliculin
Dihydromenformon
Dihydrotheelin
Dihydroxyesterin
Dihydroxyestrin
Dihydroxyoestrin
Dimenformon
Diogyn
Diogynets
Divigel
Divigel (TN)
E 2
E 8875
E(sub 2)
E0025
E1024_SIGMA
E1132_SIGMA
E2257_SIGMA
E2758_SIGMA
E8875_SIGMA
EINECS 200-023-8
EU-0100503
Elestrin
Encore
Epiestriol 50
Esclim
Estra-1,3,5(10)-triene-3,17b-diol
Estrace
Estrace (TN)
Estraderm
Estraderm (TN)
Estraderm MX
Estraderm TTS
Estraderm TTS 100
Estraderm TTS 50
Estradiol
Estradiol [USAN:INN]
Estradiol-17 beta
Estradiol-17-beta
Estradiol-17.beta.
Estradiol-17beta
Estradiol-3,17beta
Estradiolo
Estradiolo [DCIT]
Estradiolum
Estradiolum [INN]
Estradot
Estraldine
Estrapak 50
Estrasorb
Estrasorb (TN)
Estreva
Estrifam
Estring
Estring (TN)
Estring Vaginal Ring
Estring vaginal ring
Estroclim
Estroclim 50
Estrodiolum
Estrofem 2
Estrofem Forte
Estrogel
 
Estrogel (TN)
Estrogel HBF
Estrovite
Evamist
Evorel
Extrasorb
Femanest
Femestral
Femestrol
Femogen
Fempatch
Femtrace
Femtran
Follicyclin
Gelestra
Ginedisc
Ginosedol
GynPolar
Gynergon
Gynestrel
Gynodiol
Gynoestryl
HMS1362E07
HMS1569I04
HMS1792E07
HMS1990E07
HMS2051C17
HMS2090E18
HSDB 3589
IDI1_002118
Innofem
Innofem (TN)
KBio2_000405
KBio2_002269
KBio2_002973
KBio2_004837
KBio2_005541
KBio2_007405
KBio3_000769
KBio3_000770
KBio3_002749
KBioGR_000405
KBioGR_002269
KBioSS_000405
KBioSS_002270
LMST02010001
LS-137
Lamdiol
Lio-Oid
Lopac0_000503
MLS000069494
MLS000758312
MLS001076331
Macrodiol
Macrol
Menest
Menorest
Menostar
Microdiol
MolPort-001-794-632
NCGC00091544-00
NCGC00091544-01
NCGC00091544-02
NCGC00091544-04
NCGC00091544-05
NCGC00091544-06
NCGC00091544-07
NCGC00091544-08
NCGC00091544-09
NCGC00091544-12
NCGC00179321-01
NCGC00179321-02
NSC-9895
NSC9895
Nordicol
Oesclim
Oestergon
Oestra-1,3,5(10)-triene-3,17b-diol
Oestradiol
Oestradiol Berco
Oestradiol R
Oestradiol-17-beta
Oestradiol-17.beta.
Oestradiol-17beta
Oestradiolum
Oestrogel
Oestroglandol
Oestrogynal
Ovahormon
Ovasterol
Ovastevol
Ovociclina
Ovocyclin
Ovocycline
Ovocylin
Perlatanol
Polyestradiol
Prestwick0_000441
Prestwick1_000441
Prestwick2_000441
Prestwick3_000441
Prestwick_207
Primofol
Profoliol
Profoliol B
Progynon
Progynon DH
Progynon-DH
S-21400
S1709_Selleck
SAM001247032
SK-Estrogens
SL-1100
SMP1_000121
SMR000059126
SPBio_002421
Sandrena 1
Sandrena Gel
Sisare Gel
Spectrum5_002055
Syndiol
Systen
Tradelia
Trial SAT
Trocosone
UNII-4TI98Z838E
VIVELLE-DOT
Vagifem
Vagifem (TN)
Vivelle
Vivelle (TN)
Zerella
Zesteem
Zesteen
Zumenon
[2,4,6,7-3H]-E2
[3H]-estradiol
[3H]]estradiol
b-Estradiol
beta-Estradiol
beta-Estradiol 3-sulfate
beta-Estradiol 3-sulphate
bmse000642
cMAP_000005
cis-Estradiol
cis-Oestradiol
component of Menrium
delta-Estradiol
delta-Oestradiol
estradiol
estradiol-17beta
nchembio.168-comp3
nchembio.76-comp2
nchembio775-comp2
nchembio794-comp6
nchembio860-comp1
progynon
6
NorethindroneapprovedPhase 4, Phase 29368-22-46230
Synonyms:
(17-alpha)-17-Hydroxy-19-norpregn-4-en-20-yn-3-one
(17alpha)-17-Ethynyl-17-hydroxyestra-4,8(14),9-trien-3-one
17-Ethinyl-19-nor-testosterone
17-Ethinyl-19-nortestosterone
17-Ethynyl-17-hydroxyestr-4-en-3-one
17-Ethynyl-17-hydroxyestr-4-en-3-one (ACD/Name 4.0)
17-Ethynyl-17beta-hydroxyestr-4-en-3-one
17-Ethynyl-19-Nortestosterone
17-Hydroxy-(17alpha)-19-Norpregn-4-en-20-yn-3-one
17-Hydroxy-17-alpha-19-Norpregn-4-en-20-yn-3-one
17-Hydroxy-17-alpha-19-norpregn-4-en-20-yn-3-one
17-Hydroxy-19-Nor-17alpha-pregn-4-en-20-yn-3-one
17-Hydroxy-19-nor-17-alpha-pregn-4-en-20-yn-3-one
17-Hydroxy-19-nor-17alpha-pregn-4-en-20-yn-3-one
17-alpha-Ethynyl-17-beta-hydroxy-4-estren-3-one
17-alpha-Ethynyl-17-hydroxy-4-estren-3-one
17-alpha-Ethynyl-19-norandrost-4-en-17-beta-ol-3-one
17-alpha-Ethynyl-19-nortestosterone
17-alpha-Ethynyl-4-estren-17-ol-3-one
17-beta-Hydroxy-19-norpregn-4-en-20-yn-3-one
17-ethynyl-17beta-hydroxyestr-4-en-3-one
17.alpha.-Ethinyl-19-nortestosterone
17.alpha.-Ethynyl-19-nortestosterone
17.alpha.-Ethynyl-4-estren-17-ol-3-one
17alpha-Ethinyl-17alpha-Ethinyl-19-nortestosterone
17alpha-Ethinyl-19-Nortestosterone
17alpha-Ethinyl-19-nortestosterone
17alpha-Ethinylestra-4-en-17beta-ol-3-one
17alpha-Ethynyl-17-hydroxy-4-estren-3-one
17alpha-Ethynyl-17-hydroxyest-4-en-3-one
17alpha-Ethynyl-17beta-hydroxy-19-norandrost-4-en-3-one
17alpha-Ethynyl-17beta-hydroxyestr-4-en-3-one
17alpha-Ethynyl-19-nor-4-androsten-17beta-ol-3-one
17alpha-Ethynyl-19-norandrost-4-en-17beta-ol-3-one
17alpha-Ethynyl-19-nortestosterone
17alpha-Ethynyl-3-oxo-4-estren-17beta-ol
17alpha-Ethynyl-4-estren-17-ol-3-one
17alpha-ethynyl-17-hydroxy-Estr-4-en-3-one
17alpha-ethynyl-17beta-hydroxy-19-Norandrost-4-en-3-one
17alpha-pregn-4-en-20-yn-3-one
17beta-Hydroxy-17alpha-ethynylestr-4-en-3-one
17beta-Hydroxy-19-norpregn-4-en-20-yn-3-one
17α-ethinyl-19-nortestosterone
19-Nor-17-alpha-ethynyl-17-beta-hydroxy-4-androsten-3-one
19-Nor-17-alpha-ethynylandrosten-17-beta-ol-3-one
19-Nor-17-alpha-ethynyltestosterone
19-Nor-17-ethinyl testosterone
19-Nor-17-ethinyltestosterone
19-Nor-17.alpha.-ethynyltestosterone
19-Nor-17alpa-ethynyltestosterone
19-Nor-17alpha-Ethynyl-17beta-hydroxy-4-androsten-3-one
19-Nor-17alpha-Ethynylandrosten-17beta-ol-3-one
19-Nor-17alpha-ethynyl-17beta-hydroxy-4-androsten-3-one
19-Nor-17alpha-ethynylandrosten-17beta-ol-3-one
19-Nor-17alpha-ethynyltestosterone
19-Nor-ethindrone
19-Nor-ethinyl--4,5-testosterone
19-Norethindrone
19-Norethinyltestosterone
19-Norethisterone
19-nor-17α-ethynyltestosterone
4-Estren-17alpha-ethynyl-17beta-ol-3-one
46525_FLUKA
46525_RIEDEL
68-22-4
A3564/0151191
AC-11100
AC1L1IDS
AC1L1M2R
AC1NWAOX
AC1O5EOU
AC1Q6OG5
AI3-26422
AKOS004119895
AR-1C1071
ARONIS24281
Activella
Anhydrohydroxynorprogesterone
Anovulatorio
Anovule
BB_NC-0600
BPBio1_000074
BRD-A39415247-001-02-1
BRD-K92073408-001-03-3
BRN 1915671
BSPBio_000066
BSPBio_002101
Brevicon
Brevinor
Brevinor 21
Brevinor 28
Brevinor-1 21
Brevinor-1 28
C05028
CCRIS 484
CHEBI:7627
CHEMBL1162
CID4536
CID5702093
CID6230
CID6432649
CPD000499579
Camila
Camila (TN)
Ciclovulan
Conceplan
Conludaf
Conludag
D00182
DB00717
Demulen
DivK1c_000553
EINECS 200-681-6
ENT
Errin
Estrinor
Ethinyl-19-nortestosterone
Ethinylnortestosterone
Ethynylmortestosterone
Ethynylnortestosterone
Gencept
Genora
Gestest
HMS1568D08
HMS1920B10
HMS2090D21
HMS2091J10
HMS501L15
HSDB 3370
I06-0104
 
IDI1_000553
Jenest
Jenest-28
KBio1_000553
KBio2_001491
KBio2_004059
KBio2_006627
KBio3_001601
KBioGR_000637
KBioSS_001491
LMST02030097
LS-97425
Loestrin
MLS001076679
MLS001163874
MLS001304093
Menzol
Microneth
Micronett
Micronor
Micronor (TN)
Micronovum
Milli
Mini-Pe
Mini-pill
Minovlar
MolPort-002-507-131
MolPort-002-509-542
MolPort-002-728-977
MolPort-003-861-444
N.E.E
N.E.E.
N0449
N4128_SIGMA
NCGC00178820-01
NCGC00179669-01
NET
NINDS_000553
NSC-9564
NSC9564
Nelova
Nodiol
Nor-Q.D
Nor-Q.D.
Nor-QD
Nora-BE
Noraethisteronum
Noralutin
Norcept
Norcept-E
Norcolut
Norcolute
Noresthisterone
Norethadrone
Norethin
Norethin 1/35 E
Norethin 1/50 M
Norethindirone
Norethindrone
Norethindrone (USP)
Norethindrone Norethisterone
Norethindrone [USAN]
Norethisteron
Norethisterone
Norethisterone (JP15)
Norethisterone [Progestins]
Norethisteronum
Norethisteronum [INN-Latin]
Norethyndron
Norethynodron
Norethynodrone
Noretisterona
Noretisterona [INN-Spanish]
Noretisterone
Noretisterone [DCIT]
Norfor
Norgestin
Noriday
Noriday 28
Norlutate
Norluten
Norlutin
Norluton
Normapause
Norpregneninlone
Norpregneninolone
Norpregneninotone
Oprea1_606355
Orlest
Ortho 1 35
Ortho 7 7 7
Ortho-Novum 1 35
Ortho-Novum 1 50
Ortho-Novum 7 7 7
Ovysmen 0.5 35
Ovysmen 1 35
Prestwick0_000253
Prestwick1_000253
Prestwick2_000253
Prestwick3_000253
Prestwick_646
Primolut N
Primolut-N
Primolut-N (TN)
Proluteasi
SAM002564223
SC 4640
SMR000499579
SMR000718762
SPBio_001052
SPBio_002285
SPECTRUM1500437
ST094767
STK730956
STOCK1N-04274
Spectrum2_001066
Spectrum3_000521
Spectrum4_000079
Spectrum5_001198
Spectrum_001011
Synphase
Synphasic 28
Tri-Norinyl
Triella
Trinovum 21
UNII-T18F433X4S
Utovlan
Utovlar
WLN: L E5 B666 OV MUTJ E FQ F1UU1 -A&F
ZINC03814419
component of Noriday
norethindrone
7
DesogestrelapprovedPhase 48054024-22-540973
Synonyms:
(17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol
(8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-11-methylidene-1,2,3,6,7,8,9,10,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
13 Ethyl 11 methylene 18,19 dinor 17 alpha pregn 4 en 20 yn 17 ol
13-Ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol
13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol
17alpha-ethynyl-11-methylidene-18a-homo-estr-4-en-17beta-ol
54024-22-5
AC-308
AC1L24T4
AC1Q282A
C07629
C22H30O
CHEBI:4453
CHEMBL1533
CID40973
Cerazette
D017135
D02367
 
DB00304
DESOGESTREL
Desogestrel (USAN/INN)
Desogestrel [USAN:BAN:INN]
Desogestrelum
Desogestrelum [INN-Latin]
EINECS 258-929-4
HSDB 3593
LMST02030104
LS-62079
MolPort-003-846-424
NCGC00167449-01
ORG 2969
Org-2969
Org2969
Organon Brand of Desogestrel
UNII-81K9V7M3A3
ZINC04097416
alpha-pregn-4-en-20-yn-17-ol, 13-Ethyl-11-methylene-18,19-dinor-17
desogen
8
Progesteroneapproved, vet_approvedPhase 4, Phase 3, Phase 253757-83-05994
Synonyms:
(S)-4-Pregnene-3,20-dione
(S)-Pregn-4-en-3,20-dione
(S)-Progesterone
.beta.-Progesterone
.delta.(sup4)-Pregnene-3,20-dione
.delta.4-Pregnene-3,20-dione
17.alpha.-Progesterone
17a-Progesterone
17alpha-Progesterone
17alpha-progesterone
17α-progesterone
1dbb
1h60
257630-50-5
3,20-Pregnene-4
32104FB6-BF81-4F6E-83C2-024DEEAEB272
4-Pregnen-3,20-dione
4-Pregnene-3,20-dione
46665_FLUKA
46665_RIEDEL
57-83-0
753497-20-0
8012-32-6
8023-13-0
AC-700
AC1L1LKF
AI3-51682
Agolutin
Akrolutin
BB_NC-0185
BHR-100
BIDD:ER0547
BIDD:PXR0094
BPBio1_000676
BRD-K64994968-001-03-6
BSPBio_000614
Bio-luton
C00410
CCRIS 533
CHEBI:17026
CHEMBL103
CID5994
CIDR
CMC_13406
COL-1620
CPD000058345
Colprosterone
Corlutin
Corlutina
Corluvite
Corporin
Corpus Luteum Hormone
Corpus luteum hormone
Crinone
Crinone (TN)
Crinone progesterone gel
Curretab
Cyclogest
Cyclogesterin
D00066
D4-Pregnene-3,20-dione
DB00396
DR-2011
Delalutin
Delta(4)-pregnene-3,20-dione
Duraprogen
EINECS 200-350-6
ETI-411
EU-0100895
Endometrin
Estima
FE-999913
Flavolutan
Fologenon
Gelbkoerperhormon
Gesterol
Gesterol 100
Gesterol 50
Gestiron
Gestone
Gestormone
Gestron
Glanducorpin
Gynlutin
Gynoluton
Gynolutone
HMS1569O16
HMS2051O05
HMS2090J07
HSDB 3389
Hormoflaveine
Hormoluton
Hydroxyprogesterone Caproate
Hydroxyprogesterone Caproic acid
LMST02030159
LS-234
Lingusorbs
Lipo-Lutin
Lipolutin
Lopac0_000895
Lucorteum
Lucorteum Sol
Lucorteum sol
Lugesteron
Luteal hormone
Luteinique
Luteocrin normale
Luteodyn
Luteogan
Luteohormone
Luteol
Luteol (VAN)
Luteopur
Luteosan
Luteostab
Luteovis
Luteum
Lutex
Lutidon
Lutin
Lutinus
Lutociclina
Lutocuclin M
Lutocyclin
Lutocyclin M
 
Lutocyclin m
Lutocylin
Lutocylol
Lutoform
Lutogyl
Lutogynon
Lutren
Lutromone
MLS000028517
MLS000758277
MLS001074187
MLS002222367
MPA
Membrettes
Methylpregnone
Micronized Progesterone
MolPort-001-794-643
NCGC00022185-03
NCGC00022185-04
NCGC00022185-05
NCGC00022185-06
NCGC00022185-07
NCGC00022185-08
NCGC00022185-09
NCGC00090798-01
NCGC00090798-02
NCI60_042166
NSC 64377
NSC 9704
NSC-9704
NSC64377
NSC9704
Nalutron
Natural Progesterone
P 0130
P0130_SIGMA
P0478
P3972_SIGMA
P6149_SIGMA
P7556_ALDRICH
P7556_SIGMA
P8783_SIGMA
P9776_SIGMA
PROGESTERONE
Percutacrine
Percutacrine Luteinique
Piaponon
Pranone
Pregn-4-en-3,20-dione
Pregn-4-ene-3,20-dione
Pregnene-3,20-dione
Pregnenedione
Prestwick0_000477
Prestwick1_000477
Prestwick2_000477
Prestwick3_000477
Prestwick_411
Primolut
Prochieve
Progeffik
Progekan
Progestan
Progestasert
Progesterol
Progesteron
Progesterona
Progesterona [INN-Spanish]
Progesterone
Progesterone (JP15/USP/INN)
Progesterone [INN:BAN:JAN]
Progesterone [Progestins]
Progesterone, water-soluble
Progesterone-Water Soluble
Progesterone: HBC complex
Progesteronum
Progesteronum [INN-Latin]
Progestin
Progestogel
Progestol
Progeston
Progestone
Progestosol
Progestrel
Progestron
Progestronol
Progestérone
Projestaject
Prolets
Prolidon
Prolutin
Proluton
Prolutone
Prometrium
Prometrium (TN)
Prontogest
Protormone
S00293
S1705_Selleck
SAM001247039
SMR000058345
SMR000653542
SPBio_002553
SR-01000000088
SR-01000000088-5
Spectrum5_002053
Syngesterone
Syngestrets
Synovex S
Syntolutan
U 3672
UNII-4G7DS2Q64Y
Utrogest
Utrogestan
Vitarrine
WLN: L E5 B666 OV MUTJ A1 E1 FV1
ZINC04428529
beta-Progesterone
bmse000482
component of Cyclogesterin
corpus luteum hormone
delta(4)-Pregnene-3,20-dione
delta(Sup 4)-Pregnene-3,20-dione
delta(Sup4)-pregnene-3,20-dione
delta(sup 4)-Pregnene-3,20-dione
delta4-Pregnene-3,20-dione
luteohormone
nchembio.2007.53-comp14
9
MetforminapprovedPhase 4, Phase 31746657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
10
MenotropinsapprovedPhase 46061489-71-25360545
Synonyms:
61489-71-2
D02692
Human Menopausal Gonadotrophin
Human Menopausal Gonadotrophin (JP15)
 
Humegon
Humegon (TN)
LH)
MENOTROPINS
Menotropins (FSH
Menotropins (USP)
11
Leuprolideapproved, investigationalPhase 429353714-56-03911, 657181
Synonyms:
(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone
5-oxoPro-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-ProNHC2H5 dihydrate
5-oxoprolylhistidyltryptophylseryltyrosylleucylleucyl-n5-(diaminomethylidene)ornithyl-n-ethylprolinamide
AC1L1GZK
AC1L9B44
AC1Q5OPO
AR-1G9354
C07612
CID3911
CID441410
D00989
D08113
Enantone
Enantone (TN)
I04-0109
L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide
L001094
 
L002030
Leuprolide
Leuprolide acetate
Leuprolide acetate (USAN)
Leuprorelin
Leuprorelin (INN)
Leuprorelin acetate (JAN)
Leuprorelina
Leuproreline
Leuprorelinum
Lupron (TN)
N-[1-[[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
NSC377526
NSC746847
PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-NHC2H5
PGlu-his-trp-ser-tyr-D-leu-leu-arg-pro-nhet
acetic acid
leuprolide
12
Ethinyl EstradiolapprovedPhase 471257-63-65991
Synonyms:
17 alpha-Ethinylestradiol
17 alpha-Ethynylestradiol
17 alpha-Ethynyloestradiol
17 alpha-ethinyestradiol
17-Ethinyl-3,17-estradiol
17-Ethinyl-3,17-oestradiol
17-Ethinylestradiol
17-Ethynylestradiol
17-Ethynylestradiol ram
17-Ethynyloestradiol
17-alpha-Ethinyl-17-beta-estradiol
17-alpha-Ethynyl-17-beta-oestradiol
17-alpha-Ethynylestradiol
17-alpha-Ethynylestradiol-17-beta
17-alpha-ethynyl estradiol
17-ethinyl-3,17-estradiol
17-ethinyl-3,17-oestradiol
17-ethinylestradiol
17.alpha.-Ethinyl-17.beta.-estradiol
17.alpha.-Ethinylestradiol
17.alpha.-Ethynyl-17.beta.-oestradiol
17.alpha.-Ethynylestradiol
17.alpha.-Ethynylestradiol-l7.beta.
17.alpha.-Ethynyloestradiol
17.alpha.-Ethynyloestradiol-17.beta.
17a-Ethinyl-17b-estradiol
17a-Ethinylestradiol
17a-Ethynyl-17b-oestradiol
17a-Ethynylestradiol
17a-Ethynylestradiol-l7b
17a-Ethynyloestradiol
17a-Ethynyloestradiol-17b
17alpha-Ethinyl estradiol
17alpha-Ethinylestradiol
17alpha-Ethinylestradiol-17beta
17alpha-Ethynylestradiol
17alpha-Ethynyloestradiol
17alpha-Ethynyloestradiol-17beta
17α-ethynylestradiol
406932-93-2
46263_FLUKA
46263_RIEDEL
57-63-6
77538-56-8
AC-2169
AC1L1LK6
AI3-52941
Aethinyloestradiolum
Aethinyoestradiol
Aethinyoestradiol [German]
Alora
Amenoron
Amenorone
Anovlar
BIDD:ER0162
BRN 2419975
Bio-0610
C07534
CCRIS 286
CHEBI:4903
CHEMBL691
CID5991
CPD000058319
Certostat
Chee-O-Gen
Chee-O-Genf
Cyclosa
D004997
D00554
DB00977
Dicromil
Diognat-E
Diogyn E
Diogyn-E
Diprol
Dyloform
E4876_SIGMA
EE
EE(sub 2)
EE2
EINECS 200-342-2
EO
ETHINYLESTRADIOL
Effik Brand of Ethinyl Estradiol
Ertonyl
Esclim
Esteed
Estigyn
Estinyl
Estinyl (TN)
Eston-E
Estopherol
Estoral
Estoral (Orion)
Estoral (VAN)
Estoral [Orion]
Estoral {[Orion]}
Estorals
Estradiol, Ethinyl
Estradiol, Ethynyl
Estring
Estrogen
Ethidol
Ethinoral
Ethinyl E2
Ethinyl Estradiol Hemihydrate
Ethinyl Estradiol [USP]
 
Ethinyl Estradiol, (8 alpha)-Isomer
Ethinyl Oestradiol Effik
Ethinyl estradiol
Ethinyl estradiol (USP)
Ethinyl-Oestradiol Effik
Ethinyl-Oestranol
Ethinyl-oestranol
Ethinylestradiol
Ethinylestradiol (JP15/INN)
Ethinylestradiol Jenapharm
Ethinylestradiol [INN:BAN:JAN]
Ethinylestradiolum
Ethinylestradiolum [INN-Latin]
Ethinylestriol
Ethinyloestradiol
Ethinyloestradiol [Steroidal oestrogens]
Ethy 11
Ethynyl estradiol
Ethynylestradiol
Ethynylestradiol, Ethinyl Estradiol
Ethynyloestradiol
Eticyclin
Eticyclol
Eticylol
Etinestrol
Etinestryl
Etinilestradiol
Etinilestradiol [INN-Spanish]
Etinilestradiolo
Etinilestradiolo [DCIT]
Etinoestryl
Etistradiol
Etivex
Evra
Feminone
Fempatch
Follicoral
Ginestrene
Gynodiol
Gynolett
HMS2051I19
HSDB 3587
Halodrin
Hemihydrate, Ethinyl Estradiol
Inestra
Innofem
Jenapharm Brand of Ethinyl Estradiol
Jenapharm, Ethinylestradiol
Kolpolyn
LMST02010036
LS-231
Linoral
Lynoral
MLS000028479
MLS000758274
Marvelon
Menolyn
Menostar
Mercilon
Microfollin
Microfollin Forte
MolPort-001-794-636
NCGC00091533-01
NCGC00091533-04
NCGC00091533-05
NCI60_000234
NSC-10973
NSC10973
Neo-Estrone
Nogest-S
Novestrol
OVULEN-21
OVULEN-28
Oradiol
Orestralyn
Orestrayln
Organon Brand of Ethinyl Estradiol
Ortho-Cyclen
Ovex
Oviol
PUBERTAL ETHINYL ESTRADIOL STUDY
Palonyl
Perovex
Primogyn
Primogyn C
Primogyn M
Progynon C
Progynon M
Prosexol
S1625_Selleck
SAM001247008
SGCUT00127
SMR000058319
Schering Brand of Ethinyl Estradiol
Spanestrin
Thiuram E
Thiuranide
UNII-423D2T571U
Vagifem
Varnoline
WLN: L E5 B666TTT&J E1 FQ F1UU1 OQ
Ylestrol
component of Demulen
component of Oracon
component of Ortrel
ethinyl estradiol
ethynyl estradiol
to_000048
13
LoperamideapprovedPhase 4, Phase 214353179-11-63955
Synonyms:
2-methoxyethyl1-methylethyl2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
34552-83-5 (mono-hydrochloride)
4-(4-Chlorophenyl)-N,N-dimethyl-.alpha.,.alpha.-diphenyl-4-hydroxy-1-piperidinebutanamide
4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide
5-21-02-00379 (Beilstein Handbook Reference)
53179-11-6
AB00053697
AC1L1H38
AKOS000573892
Apo-Loperamide
BAS 01889668
BPBio1_000274
BRD-K61250553-001-02-9
BRD-K61250553-003-05-8
BRN 1558273
BSPBio_000248
BSPBio_001381
BSPBio_002769
Bio1_000082
Bio1_000571
Bio1_001060
Bio2_000101
Bio2_000581
C07080
C29H33ClN2O2
CAS-34552-83-5
CBiol_001796
CHEBI:162259
CHEBI:6532
CHEMBL841
CID3955
D08144
DB00836
Diamide (TN)
Diarr-Eze
DivK1c_000215
EINECS 258-416-5
HMS1791F03
HMS1989F03
HMS2089C13
IDI1_000215
IDI1_033851
Imodium A-D
Imodium A-D Caplets
Ioperamide
KBio1_000215
KBio2_000101
KBio2_000854
KBio2_002669
KBio2_003422
KBio2_005237
KBio2_005990
KBio3_000201
 
KBio3_000202
KBio3_001989
KBioGR_000101
KBioGR_001685
KBioSS_000101
KBioSS_000854
Kaopectate II
L000709
LS-114352
Lopac-L-4762
Lopac0_000708
Loperacap
Loperamid
Loperamida
Loperamida [INN-Spanish]
Loperamide (INN)
Loperamide Monohydrochloride
Loperamide [INN:BAN]
Loperamide hydrochloride
Loperamidum
Loperamidum [INN-Latin]
Lopéramide
Maalox Anti-Diarrheal
MolPort-001-969-016
NCGC00015608-01
NCGC00015608-08
NCGC00016828-01
NCGC00024818-01
NCGC00024818-02
NCGC00024818-03
NCGC00024818-04
NCGC00024818-05
NINDS_000215
Nu-Loperamide
Oprea1_109220
PMS-Loperamide
Pepto Diarrhea Control
Prestwick0_000144
Prestwick1_000144
Prestwick2_000144
Prestwick3_000144
R-18553
Rho-Loperamide
SPBio_001816
SPBio_002187
ST095179
Spectrum2_001738
Spectrum3_001015
Spectrum4_001143
Spectrum5_001374
Spectrum_000374
Tocris-0840
UNII-6X9OC3H4II
loperamide
nchembio.559-comp8
nchembio.79-comp7
14
Glycerolexperimental, approvedPhase 422356-81-5753
Synonyms:
1,2,3-Trihydroxypropane
1,2,3-propanetriol
1,2,3-trihydroxypropane
Bulbold
Cristal
E 422
Emery 916
Glyceol Opthalgan
Glycerin
Glycerin, anhydrous
Glycerin,anhydrous
Glycerine
Glycerinum
 
Glyceritol
Glycerol
Glycyl alcohol
Glyrol
Glysanin
IFP
Incorporation factor
Mackstat H 66
Monoctanoin component D
Osmoglyn
Pricerine 9091
Propanetriol
RG-S
Trihydroxypropane
Tryhydroxypropane
15Anti-Infective Agents, LocalPhase 41785
16Polyestradiol phosphatePhase 4, Phase 2, Phase 31283
17Anabolic AgentsPhase 4, Phase 2, Phase 1, Early Phase 1499
18Anti-Infective AgentsPhase 4, Phase 2, Phase 3, Phase 121402
19silver nitratePhase 414
20AnestheticsPhase 4, Phase 3, Phase 29001
21Contraceptives, OralPhase 4, Phase 3, Phase 21292
22Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 13868
23VaccinesPhase 4, Phase 3, Phase 2, Phase 16428
24EstrogensPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 12470
25Norethindrone acetatePhase 4, Phase 293
26Estradiol valeratePhase 4, Phase 2, Phase 31283979-32-8
27ProgestinsPhase 4, Phase 2, Phase 3546
28Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112767
29Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15407
30Contraceptive AgentsPhase 4, Phase 3, Phase 21901
31AndrogensPhase 4, Phase 2, Phase 1, Early Phase 11275
32HormonesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113979
33Estradiol 3-benzoatePhase 4, Phase 2, Phase 31283
34Estradiol 17 beta-cypionatePhase 4, Phase 2, Phase 31283
35Contraceptive Agents, MalePhase 4, Phase 3, Phase 2224
36Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 112778
37Gastrointestinal AgentsPhase 4, Phase 3, Phase 28109
38Pharmaceutical SolutionsPhase 4, Phase 3, Phase 27793
39Hypoglycemic AgentsPhase 45733
40Fertility AgentsPhase 4, Phase 3, Phase 2493
41
LactitolPhase 4332585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
42Follicle Stimulating HormonePhase 4157
43Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combinationPhase 437
44Chorionic GonadotropinPhase 4, Phase 2188
45NorinylPhase 437
46CatharticsPhase 4, Phase 2520
47Calcium, DietaryPhase 4, Phase 3, Phase 25525
48LaxativesPhase 4, Phase 2520
49Contraceptives, Oral, CombinedPhase 4625
50Tin FluoridesPhase 4246

Interventional clinical trials:

(show top 50)    (show all 371)
idNameStatusNCT IDPhase
1Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic SurgeryUnknown statusNCT00719017Phase 4
2Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?Unknown statusNCT01101750Phase 4
3The Treatment of Bartholin´s Cyst or Abscess With Silver NitrateUnknown statusNCT00786461Phase 4
4Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and GoserelinUnknown statusNCT01738724Phase 4
5Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical CancerCompletedNCT01988376Phase 4
6Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female SubjectsCompletedNCT00947115Phase 4
7Reactogenicity Study of Cervarix and Gardasil in UK Adolescent GirlsCompletedNCT00956553Phase 4
8Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian FailureCompletedNCT00732693Phase 4
9Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)CompletedNCT00805935Phase 4
10TOMUS-Trial Of Mid-Urethral SlingsCompletedNCT00325039Phase 4
11Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue MorcellatorsCompletedNCT00743080Phase 4
12Metformin and Oral Contraceptives in PCOSCompletedNCT00451568Phase 4
13the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)RecruitingNCT02629510Phase 4
14Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) StudyRecruitingNCT01824537Phase 4
15Contraceptive Pill and Hormonal Vaginal Ring in Women With Polycystic Ovary SyndromeRecruitingNCT01588873Phase 4
16Surgical Success After Laparoscopic vs Abdominal HysterectomyRecruitingNCT01793584Phase 4
17The Vaginal Health TrialActive, not recruitingNCT02516202Phase 4
18Study of the Elevate Apical and Posterior Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ ProlapseTerminatedNCT02123992Phase 4
19Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing ChemotherapyWithdrawnNCT00507780Phase 4
20Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic CancerUnknown statusNCT01087268Phase 3
21Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)Unknown statusNCT01095198Phase 2, Phase 3
22Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by VaginitisUnknown statusNCT01420510Phase 2, Phase 3
23Cognitive Behavioral Therapy (CBT) and Physical Exercise for Climacteric Symptoms in Breast Cancer Patients Experiencing Treatment-Induced Menopause: a Multicenter Randomized TrialUnknown statusNCT00582244Phase 3
24Single-port Access Laparoscopic-assisted Vaginal HysterectomyUnknown statusNCT01048931Phase 3
25The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial CarcinomaUnknown statusNCT01820858Phase 3
26The IMAP Study Improving Management of Mildly Abnormal Pap SmearsUnknown statusNCT00119509Phase 3
27Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal HysterectomyUnknown statusNCT01280045Phase 3
28Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the CommunityUnknown statusNCT00124878Phase 3
29Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal CancerCompletedNCT00003267Phase 3
30Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)CompletedNCT00092521Phase 3
31A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)CompletedNCT01047345Phase 3
32Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)CompletedNCT00543543Phase 3
33A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)CompletedNCT00090220Phase 3
34Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the PelvisCompletedNCT00033605Phase 3
35GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)CompletedNCT01245764Phase 3
36Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
37Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer SurvivorsCompletedNCT00981305Phase 3
38Efficacy and Safety of Clino-san on Vaginal Dryness of Breast Cancer PatientsCompletedNCT00607295Phase 3
39Pilocarpine in Treating Vaginal Dryness in Patients With Breast CancerCompletedNCT00343382Phase 3
40External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial CancerCompletedNCT00376844Phase 3
41Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast CancerCompletedNCT00026286Phase 3
42Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the UterusCompletedNCT00002706Phase 3
43Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer PreventionCompletedNCT01014026Phase 3
44ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-TrialCompletedNCT00941252Phase 2, Phase 3
45Laparoscopic vs Abdominal Radical Hysterectomy In Patients With Early Cervical CancerCompletedNCT01258413Phase 3
46Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary IncontinenceCompletedNCT01148290Phase 3
47Hyperthermia Combined Brachytherapy in CCUCompletedNCT01474356Phase 3
48A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected WomenCompletedNCT00000758Phase 3
49Radiotherapy + Metronidazole vs Radiotherapy Alone In Improving Treatment Outcomes in Advanced Cervical Cancer in UgandaCompletedNCT01937650Phase 2, Phase 3
50Biological Mesh Closure of the Pelvic Floor After Extralevator Abdomino Perineal Resection for Rectal CancerCompletedNCT01927497Phase 3

Search NIH Clinical Center for Vaginal Cancer


Cochrane evidence based reviews: vaginal neoplasms

Genetic Tests for Vaginal Cancer

About this section

Genetic tests related to Vaginal Cancer:

id Genetic test Affiliating Genes
1 Vaginal Neoplasm27

Anatomical Context for Vaginal Cancer

About this section

MalaCards organs/tissues related to Vaginal Cancer:

36
Testes, Cervix, Uterus, Ovary, Lymph node, Liver, T cells

FMA organs/tissues related to Vaginal Cancer:

17
The vagina

Publications for Vaginal Cancer

About this section

Articles related to Vaginal Cancer:

(show top 50)    (show all 127)
idTitleAuthorsYear
1
Prognostic Factors in Primary Vaginal Cancer: A Single Institute Experience and Review of Literature. (27486283)
2016
2
Vulvar and Vaginal Cancer, Vulvar Intraepithelial Neoplasia 3 and Vaginal Intraepithelial Neoplasia 3: Experience of a Referral Institute. (27430086)
2016
3
Breast metastasis from vaginal cancer. (27444140)
2016
4
Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review. (27536721)
2016
5
The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. (26790773)
2016
6
Radical Hysterectomy and Total Abdominal Vaginectomy for Primary Vaginal Cancer. (26825828)
2016
7
Role of Radical Surgery in Early Stages of Vaginal Cancer-Our Experience. (27327154)
2016
8
High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). (27010135)
2016
9
Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis. (26970567)
2016
10
Outcomes with image-based interstitial brachytherapy for vaginal cancer. (27321150)
2016
11
Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). (26768782)
2016
12
Vaginal cancer possibly caused by pessary and immunocompromised condition: Multiple risk factors may influence vaginal cancer development. (26914159)
2016
13
Brachytherapy improves survival in primary vaginal cancer. (27036631)
2016
14
Management of Vaginal Cancer. (26411952)
2015
15
Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer. (25456026)
2015
16
Sarcoid-like reaction mimicking vaginal cancer recurrence. (26420533)
2015
17
Vaginal Intraepithelial Neoplasia: Histopathological Upgrading of Lesions and Evidence of Occult Vaginal Cancer. (26461231)
2015
18
Vulval and vaginal cancer in pregnancy. (26526939)
2015
19
Staging for vaginal cancer. (25847318)
2015
20
LASER VAPORIZATION IN VULVAR INTRAEPITHELIAL NEOPLASIA (VIN), VAGINAL INTRAEPITHELIAL NEOPLASIA (VAIN) AND CONDYLOMATA ACUMINATA: IGCS-0093 Vulvar and Vaginal Cancer. (25955950)
2015
21
Primary vaginal cancer: role of MRI in diagnosis, staging and treatment. (25966291)
2015
22
PROGNOSTIC SIGNIFICANCE OF TUMOR SIZE IN SQUAMOUS CELL CARCINOMA OF THE VULVA: IGCS-0107 Vulvar and Vaginal Cancer. (25955951)
2015
23
Patterns of care and brachytherapy boost utilization for vaginal cancer in the United States. (25413431)
2015
24
Definitive radiotherapy for primary vaginal cancer: correlation between treatment patterns and recurrence rate. (25614068)
2015
25
HDR brachytherapy for the reirradiation of cervical and vaginal cancer: Analysis of efficacy and dosage delivered to organs at risk. (24161366)
2014
26
Vaginal cancer in a patient with complicated prolapse history: a case report. (25181382)
2014
27
Successful pregnancy after uterus-sparing chemoradiation therapy for vaginal cancer. (25432539)
2014
28
Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. (24423603)
2014
29
Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. (24505474)
2014
30
Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. (24785610)
2014
31
Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: A National Cancer Data Base (NCDB) study. (25281493)
2014
32
Uterine prolapse complicated by vaginal cancer: a case report and literature review. (24481208)
2014
33
Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer. (25254565)
2014
34
Improved survival in p16-positive vaginal cancers across all tumor stages but no correlation with MIB-1. (25319982)
2014
35
Dosimetric comparison of multichannel with one single-channel vaginal cylinder for vaginal cancer treatments with high-dose-rate brachytherapy. (24080298)
2013
36
HLA-G 3'UTR polymorphisms in high grade and invasive cervico-vaginal cancer. (23228396)
2013
37
A case of vaginal cancer with uterine prolapse. (25371880)
2013
38
Vaginal cancer with multiple liver and pulmonary metastases that achieved long-term survival. (24396823)
2013
39
Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer? (23212765)
2013
40
Concurrent chemoradiation for vaginal cancer. (23762284)
2013
41
Is there a place for sentinel technique in treatment of vaginal cancer?: feasibility, clinical experience, and results. (24177255)
2013
42
Vaginal cancer: the experience from 2 large academic centers during a 15-year period. (23609592)
2013
43
Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer. (23453679)
2013
44
Acr appropriateness Criteria management of vaginal cancer. (24575547)
2013
45
American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer. (22265440)
2012
46
Vulvar and vaginal cancer. (22640712)
2012
47
Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer. (22943045)
2012
48
Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results. (21868174)
2012
49
Vaginal cancer following etoposide-containing chemotherapy for metastatic gestational trophoblastic tumour. (22296447)
2012
50
Three-dimensional image-based high-dose-rate interstitial brachytherapy for vaginal cancer. (21665553)
2012

Variations for Vaginal Cancer

About this section

Cosmic variations for Vaginal Cancer:

8 (show top 50)    (show all 53)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM715FGFR3cervix,NS,carcinoma,squamous cell carcinomac.746C>Gp.S249C5
2COSM518KRAScervix,NS,carcinoma,squamous cell carcinomac.34G>Cp.G12R5
3COSM43896TP53cervix,NS,carcinoma,squamous cell carcinomac.818G>Cp.R273P5
4COSM580NRAScervix,NS,carcinoma,squamous cell carcinomac.181C>Ap.Q61K5
5COSM49175FGFR2cervix,NS,carcinoma,squamous cell carcinomac.1976A>Tp.K659M5
6COSM499HRAScervix,NS,carcinoma,squamous cell carcinomac.182A>Gp.Q61R5
7COSM763PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1633G>Ap.E545K5
8COSM12459PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1637A>Gp.Q546R5
9COSM483HRAScervix,NS,carcinoma,squamous cell carcinomac.35G>Tp.G12V5
10COSM10725TP53cervix,NS,carcinoma,squamous cell carcinomac.701A>Gp.Y234C5
11COSM13646CDKN2Acervix,NS,carcinoma,squamous cell carcinomac.392G>Tp.R131L5
12COSM773PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.3129G>Tp.M1043I5
13COSM10648TP53cervix,NS,carcinoma,squamous cell carcinomac.524G>Ap.R175H5
14COSM44029TP53cervix,NS,carcinoma,squamous cell carcinomac.550G>Ap.D184N5
15COSM480HRAScervix,NS,carcinoma,squamous cell carcinomac.34G>Ap.G12S5
16COSM45507TP53cervix,NS,carcinoma,squamous cell carcinomac.806G>Cp.S269T5
17COSM760PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1624G>Ap.E542K5
18COSM10889TP53cervix,NS,carcinoma,squamous cell carcinomac.536A>Gp.H179R5
19COSM29464STK11cervix,NS,carcinoma,squamous cell carcinomac.169G>Tp.E57*5
20COSM497HRAScervix,NS,carcinoma,squamous cell carcinomac.181C>Gp.Q61E5
21COSM775PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.3140A>Gp.H1047R5
22COSM10705TP53cervix,NS,carcinoma,squamous cell carcinomac.586C>Tp.R196*5
23COSM10659TP53cervix,NS,carcinoma,squamous cell carcinomac.817C>Tp.R273C5
24COSM11356TP53cervix,NS,carcinoma,squamous cell carcinomac.726C>Gp.C242W5
25COSM12458PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1634A>Cp.E545A5
26COSM46185TP53cervix,NS,carcinoma,squamous cell carcinomac.775G>Cp.D259H5
27COSM17442PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1624G>Cp.E542Q5
28COSM5731CTNNB1cervix,NS,carcinoma,squamous cell carcinomac.113G>Cp.G38A5
29COSM29465STK11cervix,NS,carcinoma,squamous cell carcinomac.320A>Gp.H107R5
30COSM45259TP53cervix,NS,carcinoma,squamous cell carcinomac.301A>Tp.K101*5
31COSM5662CTNNB1cervix,NS,carcinoma,squamous cell carcinomac.110C>Tp.S37F5
32COSM43662TP53cervix,NS,carcinoma,squamous cell carcinomac.868C>Ap.R290S5
33COSM766PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1636C>Ap.Q546K5
34COSM10749TP53cervix,NS,carcinoma,squamous cell carcinomac.830G>Tp.C277F5
35COSM1168056PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.3145G>Tp.G1049C5
36COSM552KRAScervix,NS,carcinoma,squamous cell carcinomac.182A>Gp.Q61R5
37COSM3734673STK11cervix,NS,carcinoma,squamous cell carcinomac.597G>Cp.E199D5
38COSM12469CDKN2Acervix,NS,carcinoma,squamous cell carcinomac.244G>Ap.V82M5
39COSM5730CTNNB1cervix,NS,carcinoma,squamous cell carcinomac.122C>Ap.T41N5
40COSM11483TP53cervix,NS,carcinoma,squamous cell carcinomac.848G>Ap.R283H5
41COSM551KRAScervix,NS,carcinoma,squamous cell carcinomac.182A>Cp.Q61P5
42COSM555KRAScervix,NS,carcinoma,squamous cell carcinomac.183A>Tp.Q61H5
43COSM10662TP53cervix,NS,carcinoma,squamous cell carcinomac.743G>Ap.R248Q5
44COSM43624TP53cervix,NS,carcinoma,squamous cell carcinomac.875A>Gp.K292R5
45COSM43660TP53cervix,NS,carcinoma,squamous cell carcinomac.719G>Tp.S240I5
46COSM517KRAScervix,NS,carcinoma,squamous cell carcinomac.34G>Ap.G12S5
47COSM13778CDKN2Acervix,NS,carcinoma,squamous cell carcinomac.376G>Ap.V126I5
48COSM120958NFE2L2cervix,NS,carcinoma,squamous cell carcinomac.235G>Cp.E79Q5
49COSM521KRAScervix,NS,carcinoma,squamous cell carcinomac.35G>Ap.G12D5
50COSM5089PTENcervix,NS,carcinoma,squamous cell carcinomac.517C>Tp.R173C5

Expression for genes affiliated with Vaginal Cancer

About this section
Search GEO for disease gene expression data for Vaginal Cancer.

Pathways for genes affiliated with Vaginal Cancer

About this section

GO Terms for genes affiliated with Vaginal Cancer

About this section

Sources for Vaginal Cancer

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet